Psychedelics After Stroke: What Is Actually Known
This is the question in our name, and it is the question we get asked most.
Here is the whole of it, including the parts that are disappointing.
The Short Version
In the research we have reviewed, we have not identified human evidence that psilocybin, DMT, Ketamine, or another psychedelic improves stroke recovery or a stroke outcome.
What does exist: human trial evidence in other conditions, especially depression. Animal studies exploring psychedelics in experimental stroke. And a Phase 1 study at Johns Hopkins evaluating the safety of psilocybin in chronic stroke survivors.
There is real reason to take the question seriously.
There is no reason yet to believe the answer.
Why Psychedelics for Stroke Recovery Became a Real Question
The strongest human evidence is in psychiatry, especially depression, and some of it is rather compelling.
In a 2023 trial published in JAMA, 104 adults with major depressive disorder were randomly assigned to a single 25 mg dose of psilocybin or an active placebo, each given alongside psychological support. Depression scores in the psilocybin group fell substantially further – a difference of about 12 points on a 60-point scale six weeks later. More people had a sustained response, though not sustained remission. There were no serious treatment-emergent adverse events, but adverse events overall were more common with psilocybin.
In an earlier Johns Hopkins trial, 51 people with life-threatening cancer received a high dose and a very low dose of psilocybin in a randomized, double-blind crossover design. About 80% still showed clinically significant reductions in depression and anxiety six months later.
Researchers have also begun studying psilocybin in neurological conditions that had previously received little psychedelic research. A 2025 open-label pilot gave psilocybin with psychotherapy to twelve people with Parkinson's disease and depression or anxiety. It had no control group. Two participants experienced severe anxiety during a session.
What This Does Not Show
None of these studies tested psilocybin for stroke recovery.
Depression is not stroke, Parkinson's disease is not stroke, and a result in one condition does not transfer automatically to another.
That transfer is exactly the open question, not an assumption we are entitled to make.
Note also what these psilocybin trials actually tested: a drug given together with psychological support, not a drug on its own.
What Stroke Research Actually Shows
In animals. DMT and psilocybin have both produced encouraging findings in experimental stroke models. DMT studies have reported reduced brain injury alongside neuroprotective effects and functional recovery. A psilocybin rat study reported reduced brain infarction and improved locomotor behavior.
In humans. A Phase 1 study at Johns Hopkins is evaluating the safety and tolerability of psilocybin in people with chronic stroke. Its primary safety measures are largely cardiovascular, including blood pressure, heart rate, oxygen saturation and ECG changes.
What this does not show
The animal work is primarily studying acute neuroprotection around the time of an experimentally induced stroke.
Most people reading this page had their stroke months or years ago.
Those are very different questions.
Animal findings do not establish that psychedelics improve chronic stroke recovery in humans.
And the Johns Hopkins study is principally asking whether psilocybin can be studied safely in stroke survivors. That question has to come before whether it helps.
PSI has no involvement in that study.
Psilocybin, Neuroplasticity and Stroke Recovery
Neuroplasticity is one of the mechanisms most often invoked when people ask whether psychedelics could support stroke recovery.
Human evidence is more complicated.
A 2026 study using PET imaging found no statistically significant increase in a marker of synaptic density after psilocybin. Another 2026 study in healthy volunteers found some anatomical changes and increased cognitive flexibility one month after a high dose, while lasting functional brain changes were largely absent.
That does not mean psilocybin has no effect on human neuroplasticity.
It means the simple story — psychedelics grow connections, therefore they should help the injured brain recover — is ahead of the evidence.
A note on microdosing after stroke: animal research has raised interesting questions about whether the duration of psychedelic-induced plasticity may relate to the duration of the acute drug experience. That does not prove microdosing is ineffective. It does mean we should not assume that sub-perceptual dosing produces the same effects as the doses studied in psychedelic therapy.
And on ibogaine, which comes up often: in one widely cited study of psychedelic-induced structural plasticity, ibogaine was the only compound tested that did not increase neurite growth.
Psilocybin remains an investigational drug and is not FDA-approved as a medication in the United States.
Psychedelic Safety After Stroke
Stroke survivors are not a general population.
The specific concerns are especially cardiovascular and neurological.
Psychedelics can acutely affect blood pressure and heart rate, and direct safety evidence in people with cardiovascular disease remains limited. The long-term cardiovascular safety of repeated psychedelic microdosing is also not well established.
You can see the concern in how researchers design studies. The Parkinson's trial closely monitored cardiovascular effects. The Johns Hopkins stroke study makes cardiovascular measures central to its safety assessment.
Ibogaine deserves its own section: it has been associated with fatal cardiac arrhythmia. A study in veterans with traumatic brain injury paired it with magnesium in an attempt to reduce that risk, and the authors were careful to say only that this may mitigate the concern.
Many stroke survivors also take medications that affect clotting or blood pressure, have a history of vascular injury, or carry seizure risk.
There is little direct evidence addressing these combinations with psychedelics in stroke survivors.
Where We Stand
We think this is a serious question.
Serious enough to have built an organization around asking it properly.
We do not think it has been answered, and we will not describe it as answered in order to sound more useful than we are.
We do not supply, source or help anyone obtain any substance, in any jurisdiction, under any circumstances.
We do not tell anyone what to take, or at what dose.
There is no protocol on this website, and that is deliberate.
If you are considering psilocybin after stroke, microdosing after stroke, DMT or another psychedelic, some useful things we can offer is the set of questions worth taking to your own doctor:
your cardiovascular history
current medications and possible interactions
mental health history
seizure risk
the legal position where you live.
We would rather you had that conversation than a sugar-coated experience on our website.
Explore the Evidence and PSI's Stroke Research